Viking Therapeutics, Inc. (NASDAQ:VKTX) clinical-stage biopharmaceutical firm, is expected to report third quarter earnings results, after market close, on Wednesday 28th October 2020.
Analysts polled by Thomson Reuters anticipate third quarter loss of $ 0.15 per share.
Looking ahead, the full year loss are expected at $ 0.59 per share.
Stock Performance
Shares of Viking Therapeutics, Inc. traded low $ -0.01 or -0.18 percent on Tuesday, reaching $ 5.57 with volume of 1.29 million shares. Viking Therapeutics, Inc. has traded high as $ 5.72 and has cracked $ 5.48 on the downward trend
According to the previous trading day, closing price of $ 5.57, representing a 71.17 % increase from the 52 week low of $ 3.26 and a 37.09 % decrease over the 52 week high of $ 8.87.
The company has a market capital of $ 405.26 million and is part of the Healthcare sector and Biotechnology industry.
Recent Analyst recommendations
- On 31st August 2020, maintained by Chardan Capital at Buy rating, with $ 20.00 target price.
Conference Call
Viking Therapeutics, Inc. will be hosting a conference call at 4:30 PM eastern time on 28th October 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.vikingtherapeutics.com
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta, which is in Phase II clinical trials to treat patients with non-alcoholic fatty liver disease and elevated low-density lipoprotein cholesterol. The companys lead drug candidate also includes VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery.
